Tumor suppressor WWOX binds to DNp63a and sensitizes cancer cells to chemotherapy by Salah, Z. et al.
Tumor suppressor WWOX binds to DNp63a and
sensitizes cancer cells to chemotherapy
Z Salah1,2, T Bar-mag1, Y Kohn1, F Pichiorri3, T Palumbo3,5, G Melino4 and RI Aqeilan*,1,3
The WWOX tumor suppressor is a WW domain-containing protein. Its function in the cell has been shown to be mediated, in part,
by interacting with its partners through its first WW (WW1) domain. Here, we demonstrated that WWOX via WW1 domain interacts
with p53 homolog,DNp63a. This protein–protein interaction stabilizesDNp63a, through antagonizing function of the E3 ubiquitin
ligase ITCH, inhibits nuclear translocation of DNp63a into the nucleus and suppresses DNp63a transactivation function.
Additionally, we found that this functional crosstalk reverses cancer cells resistance to cisplatin, mediated by DNp63a, and
consequently renders these cells more sensitive to undergo apoptosis. These findings suggest a functional crosstalk between
WWOX and DNp63a in tumorigenesis.
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The WW domain-containing oxidoreductase (WWOX) gene
encodes a 46-kDa tumor suppressor.1,2 WWOX contains two
N-terminal WW domains and a central short dehydrogenase
reductase domain. Through its first WW (WW1) domain,
WWOX interacts with a growing list of partners, and thus
involved in different signaling pathways ranging from growth
suppression, differentiation, and transcription modulation.
WWOX binds the proline-rich motif (PPxY) found in a number
of proteins. Among these partners are p73, Ap2a, Ap2g,
ErbB4, Jun, and Runx2.1,2
The gene spans the fragile site FRA16D that includes a
genomic region involved in chromosome translocation in
multiple myelomas and in hemi- and homozygous deletions
in cancers and cancer-derived cell lines; in addition, theWWOX
promoter region is frequently hypermethylated in cancers.3,4
Wwox-knockoutmice demonstrated thatWWOX functions as a
bona fide tumor suppressor. Spontaneous osteosarcomas in
juvenile Wwox-knockout and lung papillary and mammary
carcinomas in adultWwox-heterozygous mice were observed.
Additionally, Wwox-heterozygous mice significantly develop
more ethyl nitrosourea-induced lung tumors and B-cell
lymphomas and more N-nitrosomethylbenzylamine-induced
forestomach tumors in comparison with WT littermates.5–8
p63 is a member of the p53 family that includes p53, p63,
and p73 proteins.9,10 It is a family of transcription factors that
are highly homologous with very distinct functions. In general,
all members of the family have three structural domains that
are essential for their function: a DNA-binding domain (DBD),
an oligomerization domain (OD) (all function as tetramers),
and a transactivation domain (TA). The use of a second
promoter generates N-terminal truncated isoforms that in p73
and p63 lack the TA domain (DN isoforms).
The most common isoform of p63 is a truncated gene
product termed DNp63. Whereas the TAp63 proteins are
capable of transactivation, the DNp63 forms can also act in a
dominant-negative fashion to counteract the transcriptional
activity of the TAp63 isoforms and p53.9,10 This isoform is
highly expressed in basal or reserve cells, immature squa-
mous epithelium, and epithelial stem cells. Both DNp63 and
TAp63 can be subdivided further into three unique C-terminal
sequence variants, conveniently designated as a, b, and g,
yielding a total of six discrete p63 gene products. The major
functioning isoform is DNp63a. DNp63a is essential to the
formation of the epidermis and its appendages, such as hairs
and sebaceous glands since it regulates epithelial develop-
ment and differentiation.11–13 Most tumors (480% of primary
head and neck squamous cell carcinomas (HNSCCs), as well
as other squamous cell epithelial malignancies and non-small
cell lung cancer) retain p63 expression, where it is often
overexpressed and occasionally amplified. Of note, DNp63a is
the predominant isoform at the protein level.14–17 In addition,
DNp63a expression leads to chemotherapeutic reagent
resistance by different mechanisms.18–20
In this work, we show that WWOX binds DNp63a, changes
its cellular localization, inhibits its transcriptional activity, and
counteracts its chemoresistance-induced phenotype.
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Results
WWOX–DNp63 physical interaction. In previous work,21
we reported that WWOX physically and functionally interacts
via its WW1 domain with the p53 homolog, p73 through its
PPxY motif. Thus, we hypothesized that WWOX, through the
same mechanism, might bind to other members of the p53
family, mainly p63 which contains a PPxY motif. To test our
hypothesis, we cotransfected HEK293 cells with either the
expression vectors encoding Myc–WWOX and HA–TAp63a
or HA–DNp63a. Cells lysates were immunoprecipitated (IP)
with anti-HA or anti-Myc antibodies followed by immunoblot-
ting (IB) with HRP-conjugated antibody to HA or Myc. The
results revealed that WWOX binds to DNp63a as determined
by immunoprecipitation with anti-Myc and IB with anti-HA
antibody (Figure 1a, upper panel, lane 7), while it failed to do
so with TAp63a (Figure 1a, upper panel, lane 4). As a control,
there were no detectable complexes in anti-IgG immunopre-
cipitates (Figure 1a, lanes 3 and 6). Of note and due to
unknown reasons, we were unable to see the interaction in
reverse (Figure 1a, lower panel).
To further confirm DNp63a–WWOX interaction, we utilized
another cell system in which HA–TAp63a or HA–DNp63a are
stably expressed in previously described tet-On-inducible
SaOS2 cells.22 SaOS2 cells were transduced with low MOI of
Ad-WWOX. Cells lysates were IP with anti-HA or anti-WWOX
antibodies followed by IBwith HRP-conjugated antibody toHA
and anti-WWOX. As shown in Figure 1b, only DNp63a was
able to interact with WWOX (lane 6 versus 3). To ultimately
prove the selective interaction of WWOX with DNp63a rather
than with TAp63a, we performed GST-pulldown assay using
bacterial GST–WWOX fusions on cell lysates extracted from
HEK293T cells transfected with either HA–TAp63a or HA–
DNp63a. Also in this experimental system, we confirmed
physical association betweenWWOXandDNp63a (Figure 1c,
lane 6 versus 3).
Since we were unable to see specific co-IP between Myc–
WWOX and HA–DNp63a in reverse using anti-HA and IB with
anti-Myc antibody (Figure 1a, lower panel), we repeated the
experiment as in Figure 1a but used antibodies against
WWOX andDNp63a for IB. Using this approach, we were able
to see specific interaction between WWOX and DNp63a in
both co-IP directions (Figure 1d). Taken together, these
results suggest that WWOX specifically binds DNp63a.
Mapping of WWOX–DNp63a interaction. To map the
region in WWOX responsible for binding to DNp63a, we did
the same IP as mentioned above using WWOX-Y33R in
which tyrosine (Y) was replaced with arginine (R) (a point
mutation in WW1 domain that was previously shown to
abrogate WWOX binding ability to its partners21). While a
physical interaction was revealed between WWOX and
DNp63a, WWOX-Y33R abolished this interaction
(Figure 2a, lane 4 versus 7), indicating that WWOX interacts
with DNp63a via its WW1 domain. Results from Figure 1c
(lane 4 versus 7) also confirm this finding. To further confirm
that WWOX interacts with DNp63a via its WW1 domain, we
cotransfected HEK293 cells with expression vectors encod-
ing HA–DNp63a and different mammalian GST–WWOX
domains (GST–WW1, GST–WW2, GST–WW1,2, GST–
SDR). Cell lysates were pulled down using GST beads
followed by IB with anti-HA–HRP-conjugated antibodies. As
shown in Figure 2b, only WW1 domain of WWOX was able to
bind to DNp63a.
We next examined whether PPxY motif within DNp63a is
responsible for WWOX–DNp63a association. Using site-
directed mutagenesis, we generated point mutations in the
PPxY motif by replacing the two prolines and tyrosine with
alanine generating DNp63a-AAxA and determined the ability
of this mutant to bind WWOX by GST-pulldown assay.
Unexpectedly, DNp63a-AAxA was still able to bind WWOX
similar to intact DNp63a (Figure 2c), suggesting that WW1
domain of WWOX binds to a different motif, rather than PPxY,
within DNp63a.
WWOX inhibits DNp63a ubiquitination and degradation
mediated by ITCH. DNp63a ubiquitination and degradation
is mediated by the ubiquitin E3-ligase ITCH.23 Since this
effect on DNp63a is dependent on ITCH WW domains and
our results here show that DNp63a interacts with WW1
domain of WWOX, we next set to examine whether
WWOX affect DNp63a ubiquitination mediated by ITCH. To
this end, HEK293 were cotransfected with HA–UB and
Myc–DNp63a alone or Myc–DNp63a and Flag–ITCH, or
Myc–DNp63a, Flag–ITCH, and WWOX. At 24 h, cells were
treated with the proteasome inhibitor MG132 for an additional
4 h. Lysates were subjected to immunoprecipitation using
anti-Myc antibody followed by IB with anti-HA–HRP
antibody. We found that while expression of ITCH increases
ubiquitination of DNp63a (Figure 3a, middle lane), coexpres-
sion of WWOX abrogated this ubiquitination event
(Figure 3a, right lane).
To prove that WWOX affects DNp63a ubiquitation by
competing on the interaction between DNp63a and ITCH,
we performed coimmunoprecipitation assay betweenDNp63a
and ITCH in the presence of either WWOX or mutant WWOX-
Y33R. To this end, we cotransfected HEK293 cells with HA–
DNp63a, Flag–ITCH, and Myc–WWOX or Myc–WWOX-
Y33R. At 24 h, cells were treated with the proteasome
inhibitor MG132 for an additional 2 h. Lysates were subjected
to immunoprecipitation using anti-HA, IgG, anti-Flag, and anti-
Myc antibodies followed by IB with HRP-conjugated antibody
to HA, Flag, or Myc. We found that while WWOX expression
reduced the interaction between DNp63a and ITCH, WWOX-
Y33R was unable to do so (Figure 3b, upper panel, lane 5
versus 10), suggesting that the presence of mutant WWOX
rescues ITCH-DNp63a association. This reduced interaction
betweenDNp63a and ITCHwasmost likely due to association
of DNp63a and WWOX, but not WWOX-Y33R (Figure 3b,
upper panel, lane 4 versus 9 andmiddle panel, lane 2 versus 7).
Notably, no change was observed when using anti-Flag
antibodies (Figure 3b, lower panel, lane 2 versus 7).
To examine whether WWOX effect on DNp63a ubiquitina-
tion affects DNp63a protein levels, we analyzed the half-life of
DNp63a in the presence or absence of WWOX using the
protein synthesis inhibitor, cycloheximide (CHX). Whereas
WWOX led to increased half-life of DNp63a, WWOX-Y33R
mutant that does not interact with DNp63a (Figure 2), had little
effect if at all, onDNp63a half-life (Figure 3c). These data were
also validated using the inducible DNp63a-expressing SaOS2
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cells. While control untransduced, Ad-GFP-transduced, and
Ad-WWOX-Y33R- transduced cells (Figure 3d) showed no
effect on DNp63a stability, cells transduced with Ad-WWOX
displayed increased DNp63a protein levels (Figure 3d). To
further confirm the importance of WWOX in controlling the
protein level of DNp63a, we generated stable HaCaT cells
clones expressing shRNA constructs specifically targeting the
human WWOX mRNA and analyzed consequences on
DNp63a levels. As shown in Figure 3e, WWOX-depleted
HaCaT (KD) cells displayed lower DNp63a levels compared
with control shRNA-expressing (EV) cells.
To further show that WWOX stabilizes DNp63a by
specifically inhibiting its degradation via the proteasome, we
did the same experiment shown in Figure 3d, except for the
use of the proteasome inhibitor MG132 prior to cell lysis. As
shown in Figure 3f (lane 2), WWOX overexpression was
associated with stabilization of DNp63a. SinceWWOX did not
bind TAp63a, we examined whether it indeed does not affect
its half-life. To this end, levels of TAp63a in the presence or
absence of WWOX and CHX was examined. We found that
neither WWOX nor WWOX-Y33R were able to affect TAp63a
stability (data not shown). Altogether, these results suggest
that WWOX antagonizes ITCH effect on DNp63a and
stabilizes its protein levels.
WWOX sequesters DNp63a in the cytoplasm. The results
obtained above led us to question the significance of the
interaction between WWOX and DNp63a. DNp63a is a
transcription factor that localizes in the nucleus, where it
binds DNA and transactivates target genes such as K14, and
BPAG-1.10 In contrast, WWOX is predominantly known as a
cytoplasmic protein,1,2 though some reports demonstrate
nuclear localization under certain conditions.24 Thus,
we asked the question about the possibility of whether
WWOX can affect DNp63a localization or vice versa. To
answer this, we studied the localization of DNp63a by
subcellular fractionation. We transfected HEK293 cells with
DNp63a in the presence or absence of WWOX. After 24 h,
we prepared lysates from both the nuclear and cytoplasmic
fractions. Successful fractionation was confirmed by the
exclusive presence of GAPDH and lamin in the cytoplasmic
and nuclear fractions, respectively. We found that, although
DNp63a alone localizes mainly in the nuclear fraction,
coexpression of DNp63a and WWOX was associated with
increased DNp63a presence in the cytoplasm concomitant
with less nuclear DNp63a levels (Figure 4a). To further
confirm this finding, we tested the distribution of DNp63a
using immunofluorescence and confocal microscopy. HeLa
cells were transiently cotransfected with GFP–WWOX and
HA–DNp63a. Localization of the HA- or GFP-tagged proteins
was then determined by immunofluorescent staining using
the appropriate antibodies. As shown in Figure 4b, when
present alone DNp63a is mainly localized in the nucleus
while WWOX is predominantly cytoplasmic. However,
when WWOX is coexpressed with DNp63a, it is sequestered
and colocalizes with WWOX in the cytoplasm (Figure 4b,
arrow heads).
To further confirm these results, we used SaOS2 cells
overexpressing both WWOX and DNp63a. Also, in these cells
WWOX colocalization withDNp63a lead to its sequestration in
the cytoplasm (Figure 4c, arrow heads). Interestingly, cells
displaying nuclear DNp63a have significantly reduced expres-
sion of WWOX (Figure 4b and c), which might explain this
partial sequestration of DNp63a. However, we cannot exclude
that there might be other factor(s) regulating DNp63a
sequestration into the cytoplasm. Altogether, our results
Figure 1 WWOX physically interacts with DNp63a but not TAp63a. (a) HEK293 cells were cotransfected with plasmids encoding Myc–WWOX and HA–TAp63a or
HA–DNp63a. After 24 h, cells were lysed and immunoprecipitation was performed as follows: lanes 2 and 5: anti-HA; lanes 3 and 6: anti-IgG; and lanes 4 and 7: anti-Myc
antibodies. Immunoblotting was done using anti-HA–HRP or anti-Myc-HRP antibodies. Lane 1 shows input of TAp63a and lane 8 shows input of DNp63a. (b) SaOS-2 cells,
stably transfected with a doxycycline-inducible vector containing the HA–TAp63a or the HA–DNp63a gene, were infected with 10 MOI of Ad5-WWOX for 24 h then induced
with doxycycline for an additional 24 h. Subsequently, cells were lysed and immunoprecipitation was performed as follows: lanes 1 and 4: anti-HA; lanes 2 and 5: anti-IgG; and
lanes 3 and 6: anti-WWOX antibodies. Immunoblotting was done using anti-HA–HRP and anti-WWOX antibodies. (c) HEK293 cells were transfected with plasmids encoding
HA–TAp63a or HA–DNp63a. After 24 h, cells were lysed and GST-pulldown was performed using GST alone (lanes 2 and 5) or GST–WWOX (lanes 3 and 6) or GST–WWOX-
Y33R (lanes 4 and 7). Lanes 1 and 8 show 2.5% of input of each lysate. (d) HEK293 cells were cotransfected with plasmids encoding HA–DNp63a and Myc–WWOX. After
24 h, cells were lysed and immunoprecipitation was performed as follows: lane 2: anti-HA; lane 3: anti-IgG; and lane 4: anti-Myc antibodies. Immunoblotting was done using
anti-p63 and anti-WWOX antibodies. Lane 1 shows 2.5% of input of lysate. A higher band in the IgG (lane #2) and Myc (lane #3) is observed in the anti-WWOX blot (lower)
likely due to antibody non-specificity
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suggest that WWOX binds DNp63a in the cytoplasm and
prevents its translocation to the nucleus.
WWOX suppresses DNp63a transactivation ability.
Since our above results demonstrate that WWOX sequesters
DNp63a in the cytoplasm, we next set to determine whether
WWOX might affect its transactivation function. To test this
hypothesis, we transfected HEK293T cells with constructs
containing the luciferase gene driven by K14 or BPAG-1
promoters that contain DNp63a response elements. At 24 h,
cells were lysed and luciferase activity was assessed. As
expected, expression of WWOX alone has no effect on
luciferase activity of these promoters while DNp63a had
significant transactivation (Figure 5a). By contrast, coexpres-
sion of WWOX with DNp63a significantly suppressed
DNp63a transactivation function in a dose-dependent man-
ner (Figure 5a). This effect was significantly attenuated when
expressing WWOX-Y33R (Figure 5b and c). Cumulatively,
our findings suggest that WWOX sequesters DNp63a in the
cytoplasm, and this is associated with its reduced transacti-
vation function.
WWOX antagonizes DNp63a-induced chemoresistance.
DNp63a was shown to play a crucial role in determining
cellular chemosensitivity,18,20,25 while WWOX was shown to
promote apoptosis in certain contexts.1,2 Considering these
findings, our results here prompted us to examine whether
WWOX affects DNp63a function in chemosensitivity, that is,
upon treatment of cisplatin. To test this, inducible-DNp63a
SaOS2 cells were stably transduced with either WWOX or
empty lentiviral vectors. Successful expression of WWOX
and DNp63a, following doxycycline (Dox) treatment, is shown
in Figure 6a. SaOS2 cells expressing DNp63a, WWOX or
both together were next treated with cisplatin for 48 h. Cells
were next collected and percentage of dead cells, assessed
by trypan blue exclusion, and apoptotic cells, as assessed by
propidium iodide using FACS analysis, was determined. We
found that treatment of cells with cisplatin induced cell death
by fourfolds (Figure 6b). Upon treatment of DNp63a-expres-
sing SaOS2 cells (Dox) with cisplatin, no significant change
was observed. Importantly, expression of WWOX and
cisplatin treatment significantly increased cell death by
eightfold (Figure 6b). Intriguingly, coexpression of DNp63a
and WWOX significantly sensitized cisplatin-treated cells to
undergo cell death/apoptosis (B14-folds) as compared with
SaOS2-expressing DNp63a alone (Figure 6b). Similar results
were obtained by examining percentage of sub-G1 popula-
tion (Figure 6c). Although these observations suggest that
WWOX antagonizes DNp63a-induced chemoresistance, it
does not explain the fact that WWOX expression alone
exhibited less percentage of cell death and apoptosis
(Figure 6b and c). To address this issue, we examined
whether Dox treatment can affect cisplatin-induced cell
growth/death. In fact, several reports have shown that Dox
by itself can induce growth arrest and apoptosis26–28 and
could enhance cisplatin effect in cancer cells.26–29 To test
this in our settings, we utilized control SaOS2 cells to
examine their sensitivity upon treatment of Dox and cisplatin.
We observed that treatment of Dox alone induces cell death
by 2.6-fold as compared with untreated cells (Figure 6d),
consistent with previously published data.26–28 Of note, while
cisplatin treatment increased cell death by sevenfold, this
effect was increased to 9.3-fold upon treatment with both Dox
and cisplatin. These results suggest that both Dox and
cisplatin has a synergistic effect on cell death in agreement
with previously published data.26–29 Taken together, our
findings suggest that WWOX attenuates DNp63a-mediated
cisplatin chemoresistance.
Discussion
The p53 family that includes in addition to p53, p63, and p73
proteins have both common and distinct functions. This family
Figure 2 WWOX via its WW1 domain interacts with DNp63a. (a) HEK293 cells
were cotransfected with plasmids encoding HA–DNp63a and Myc–WWOX or Myc–
WWOX-Y33R. After 24 h, cells were lysed and immunoprecipitation was performed
as follows: lanes 2 and 5: anti-HA; lanes 3 and 6: anti-IgG; and lanes 4 and 7: anti-
Myc antibodies. Immunoblotting was done using anti-HA–HRP or Myc-HRP
antibodies. Lanes 1 and 8 show 2.5% of input of each lysate. (b) HEK293T cells
were transiently cotransfected with the expression plasmid encoding HA–DNp63
and mammalian GST–WW1 or GST–WW2 or GST–WW1þ 2 or GST–SDR or
GST–WWOX expression vectors. At 24 h after transfection, whole-cell lysates were
prepared and complexes were captured with glutathione-sepharose, and bound
protein was detected by HA immunoblot. (c) HEK293T cells were transiently
cotransfected with the expression plasmid encoding GST–WWOX and wt DNp63a
or PY mutant HA–DNp63a (AAxA). At 24 h after transfection, whole-cell lysates
were prepared and complexes were captured with glutathione-sepharose, and
bound protein was detected by HA immunoblot
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of proteins play very important roles in cell differentiation
stemness and plasticity,30–33 in immune response regula-
tion,34 in tumorigenesis and tumor suppression,33,35–38 in
development and reproduction,39,40 DNA damage,41 and
apoptosis and cell-cycle regulation.33,42,43 In addition to
regulating each other’s function,37,44,45 the functional out-
come of these proteins are regulated by different mechan-
isms, including miRNAs, post-translational modifications, and
protein–protein interactions.43,46–48 Of particular interest, the
WW domain-containing proteins, including WWOX, YAP, and
ITCH, were shown to regulate p73 and p63 functional
outcome.21,23,49–52 Here, we further show that WWOX, via
its WW1 domain, associates with DNp63a and antagonizes
the ubiquitin E3 ligase ITCH-mediated ubiquitination and
degradation of DNp63a. Importantly, we found that WWOX
suppresses DNp63a transactivation function perhaps through
sequestering it in the cytoplasm. Consistent with these
findings, WWOX enhances chemosensitivity to cisplatin in
SaOS2 cells expressing DNp63a. Together, these findings
argue for an unforeseen functional crosstalk betweenWWOX
and DNp63a.
Previous characterization of WWOX partners revealed its
WW domains interaction with PPxY-containing proteins.1,2
Nevertheless, other non-PPxY members were also reported
including Hyaluronidase,53 Jnk1,54 Tau,55,56 and Mdm2.24
Although WW1 domain of WWOX mediates this interaction,
our results demonstrate that this is not mediated by the PPxY
motif of DNp63a. These data might suggest that WW1 domain
of WWOX might interact with other proline-rich motifs rather
than the canonical PPxY (PY) motif. In fact, it was shown
recently that classical WW domains, known to interact with
canonical PY motifs, could also bind non-canonical pSP or
pTP motifs highlighting the plasticity of WW domains
interactions.57 Further research would be necessary to
decipher and characterize these motifs.
The E3 ubiquitin ligase ITCH binds, ubiquitinates, and
promotes the degradation ofDNp63a, and a single amino-acid
substitution in the PY domain ofDNp63 (Y449F) was shown to
be sufficient to reduce its ability to interact with ITCH WW
domains. Here, we show that WWOX competes with ITCH on
binding to DNp63a and inhibits DNp63a ubiquitination
mediated by ITCH and thus increases DNp63a protein
stability. In support of this, expression of point mutant
WWOX-Y33R resulted in significant rescue of ITCH–DNp63a
interaction. In fact, we have previously shown thatWWOX can
compete with other WW domain-containing proteins, like YAP
and ITCH, for binding common target proteins, such as ErbB4
and p73, hence determining functional outcomes.49
Altogether, these findings argue that WW domain proteins
could compete with each others to determine functional
outcome of their common PY-containing targets.
For a transcription factor to be functional, it is not enough to
be expressed, but it has to have the optimal localization. Thus,
although WWOX stabilizes DNp63a protein, it inhibits its
transcriptional transactivation function, in part, by sequester-
ing it in the cytoplasm. Another possibility by which WWOX
might antagonize DNp63a is by inhibiting its dominant-
negative effect on the proapoptotic p63 isoform TAp63.
DNp63a inhibits the transcriptional activity of TAp63 by
competition for the same responsive elements or by
Figure 3 WWOX inhibits ITCH-mediated ubiquitination ofDNp63 and increases its half-life. (a) HEK293 cells were transfected with the indicated plasmids. After 24 h, cells
were treated with 20mmol/l MG132 for 4 h. Lysate was prepared and IP with anti-Myc (DNp63a) and detected with anti-HA antibodies (UB). (b) HEK293 cells were
cotransfected with plasmids encoding HA–DNp63a and Flag–ITCH and Myc–WWOX or Myc–WWOX-Y33R. After 24 h, cells were lysed and immunoprecipitation was
performed as follows: lanes 2 and 7: anti-HA; lanes 3 and 8: anti-IgG; lanes 4 and 9: anti-Myc; and lanes 5 and 10: anti-Flag antibodies. Immunoblotting was done using
anti-HA–HRP, anti-Myc_HRP, or anti-Flag-HRP antibodies. Lanes 1 and 6 show 2.5% of input of each lysate. A higher band in the IgG (lanes #3 and 8) and Flag (lanes #5 and
10) is observed in the anti-Myc blot (middle) likely due to antibody non-specificity. (c) HEK293 cells were cotransfected with WWOX andDNp63a. After 24 h, cells were treated
with 20mg/ml CHX at the indicated time points and analyzed as shown. (d) Tet-On-inducible SaOS2 cells were infected with 10 MOI of Ad5-WWOX for 24 h then induced with
doxycycline for additional 24. Cells were treated with CHX as indicated and blotted with anti-HA or anti-WWOX. Vinculin was used as loading control. (e) HaCaT cells were
transduced with lentiviral-vector of WWOX (KD) or scramble shRNA (EV) constructs. Lysates were analyzed using the indicated antibodies. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase. (f) Tet-On-inducible SaOS2 cells were used as in (d) but instead of CHX, cells were treated with the proteasome inhibitor MG132
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sequestering TAp63 in inactive hetero-tetramers (DNp63a-
TAp63 tetramers).58 Therefore, it is possible that WWOX
might disrupt the formation of these inactive hetero-tetramers,
and by this, inhibits DNp63a functions and reliefs the inhibitory
effect on TAp63. Of note, our data also indicate that WWOX
selectively binds DNp63a, but not TAp63a, perhaps due to
conformational elements that are not yet resolved.
Recent evidence shows that p63 plays an important role in
conferring either chemoresistance or chemosensitivity. While
TAp63 correlates with and induces chemosensitivity,59–61
DNp63a expression directly correlates with a poor clinical
response to cisplatin in HNSCC18 and leads to chemoresis-
tance by different mechanisms.19,20 Recently, it has been
shown that the chemotherapeutic agents cisplatin, by indu-
cing c-Abl, increases DNp63a phosphorylation and interaction
with YAP leading to DNp63a stabilization and resistance to
death.25 We show here that WWOX also binds to DNp63a,
stabilizes its protein, however, inhibits its function and leads to
more cisplatinum sensitivity. These data might suggest that
WW domain interactions might regulate DNp63a functional
outcome.
The role of DNp63 in cancer seems to be controversial.
While some evidence suggests thatDNp63 acts as a guardian
against tumor migration and metastasis,37,62,63 others sug-
gest that DNp63 correlates with more proliferative and stem
cell like cancer cell phenotypes, acts as a pro-inflammatory
factor, and correlates with poor survival.63–66 Consequently,
to fully understand the role of p53 family members in a
particular context, the integration of the activities of all the
isoforms, their modulators, and their partners must be
assessed in a context-specific manner.
In summary, we provide evidence that DNp63a andWWOX
physically interact, and that this interaction results in an
increased chemosenstivity to cisplatin and increased rate of
cell death. Additional genetic and biochemical approaches will
elucidate the biological consequences of this association in
normal and cancer cells.
Materials and Methods
Cell culture and transient transfection. HEK293, and HaCaT cells
were grown in DMEM, DNp63a-tet-ON SaOS2 in RPMI. All cells were
supplemented with 10% FBS (Gibco, Grand Island, NY, USA), glutamine, and
Figure 4 WWOX overexpression sequestersDNp63a. (a) HEK293 cells were transfected with either WWOX alone (left lane),DNp63a alone (middle lane), or WWOX and
DNp63a together (right lane). After 24 h, cells were lysed into cytoplasmic and nuclear fractions as indicated. Lamin and GAPDH were used as nuclear and cytoplasmic
fraction markers, respectively. (b) Hela cells were transfected with GFP–WWOX and HA–DNp63a. After 24 h, cells were fixed and stained using anti HA antibody.
Immunofluorescence staining was analyzed using confocal microscopy. (c) SaOS2 cells were transfected with GFP–WWOX and HA–DNp63a. After 24 h, cells were fixed and
stained using anti HA antibody. Immunofluorescence staining was analyzed using confocal microscopy
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penicillin/streptomycin (Biological Industries, Beit-Haemek, Israel). To induce
the expression of DNp63a, SaOS2 cells were treated with 2 mg/ml doxycyclin
(Sigma-Aldrich, St. Louis, MO, USA) for 48 h. All expression vectors used were
previously reported in 21, 23. Transient transfections were achieved using Mirus
TransLTi (Mirus Bio LLC, Madison, WI, USA). In all cell lines used in this article,
p53 function is lost by different mechanisms, including mutation and loss of
expression and function.
GST-pulldown, immunoprecipitation, and immunoblot analysis.
Cells were lysed by using Nonidet P-40 lysis buffer containing 50 mmol/l Tris (pH
7.5), 150 mmol/l NaCl, 10% glycerol, 0.5% Nonidet P-40, and protease inhibitors
(Sigma-Aldrich). In GST-pulldown, lysates were mixed with glutathione-sepharose
4B (GST beads) (GE Healthcare, Waukesha, WI, USA) and rocked for 2 h at 4C.
Thereafter, the beads were washed four times with the same buffer containing
0.1% Nonidet P-40. For immunoprecipitation, lysates were pre-cleared with mouse
anti-IgG (Zymed, Carlsbad, CA, USA) immunoprecipitations were carried out in the
same buffer, and lysates were washed four times with the same buffer containing
0.1% Nonidet P-40. Western blotting was conducted under standard conditions.
Antibodies used were monoclonal anti-HA (Covance, Princeton, NJ, USA),
monoclonal anti-p63 (4A4), monoclonal anti-Myc–HRP (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), monoclonal anti-Flag, anti-Flag–HRP and anti-Vinculin
(Sigma-Aldrich), anti-HA–HRP (Roche Applied Science, Indianapolis, IN, USA)
and monoclonal anti-WWOX antibodies.21
Luciferase assay. HEK293 cells seeded in 12-well plates were cotransfected
with the relevant plasmids together with different plasmids containing different
DNp63a responsive elements of various DNp63a target genes. Renilla luciferase
was used as an internal control. Cells were collected 24 h later and Firefly and
Renilla luciferase activities were assayed with Dual-Luciferase Assay System
(Promega, Madison, WI, USA). Firefly luciferase activity was normalized to Renilla
luciferase activity. All experiments were done at least thrice.
Subcellular fractionation. Nuclear and cytoplasmic extracts were prepared
as follows. First, cells were scraped in PBS, and after centrifugation, the cell pellet
was reconstituted in a hypotonic lysis buffer [10 mmol/l HEPES (pH 7.9), 10 mmol/l
KCl, 0.1 mmol/l EDTA] supplemented with 1 mmol/l DTT and a broad-spectrum
cocktail of protease inhibitors (Sigma-Aldrich). The cells were allowed to swell on
ice for 15 min, then NP40 was added, and cells were lysed by vortex. After
centrifugation, the cytoplasmic fraction was collected. Afterwards, nuclear
extracts were obtained by incubating nuclei in a hypertonic nuclear extraction
buffer (20 mmol/l HEPES (pH 7.9), 0.42 mol/l KCl, 1 mmol/l EDTA) supplemented
with1 mmol/l DTT for 15 min at 4 1C. The nuclear fraction was collected after
centrifugation.
In vivo ubiquitination assay. HEK293 cells were cotransfected with
HA–UB, Myc–DNp63a with or without Flag–ITCH or WWOX as indicated in
Figure 3a. After 24 h, cells were treated with MG-132 (Sigma; 20 lmol/l) for 4 h.
Lysates were IP using anti-Myc antibody, washed 4 times, and immunoblotted with
anti-HA–HRP.
Measurement of steady-state and half-life of DNp63 protein
level. HEK293T cells were transfected with DNp63a with or without
Figure 5 WWOX suppressesDNp63 transactivation function. (a) HEK293T cells were transiently cotransfected with the luciferase reporter construct carrying theDNp63a
responsive element derived from the promoters of K-14 and BPAG-1 in addition to either WWOX alone, DNp63a alone, or with increasing amount of WWOX. In all
experiments, empty vector was cotransfected to normalize plasmid concentration where required. At 24 h after transfection, cells were lysed and luciferase activity was
determined. Results are shown as fold induction of the luciferase activity compared with control cells transfected with empty vector alone and are the average of three
experiments. Bars represent STDV. (b, c) HEK293 cells were treated as in (a) though fixed amount of K14-Luc (b) or BPAG-1-Luc (c) and either WWOX or WWOX-Y33R
(0.5mg) and 0.1mg DNp63a. Cells were analyzed as in (a)
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Myc–WWOX. At 24 h post-transfection, cells were lysed or treated with the protein
synthesis inhibitor CHX (Sigma-Aldrich; 100lg/ml) for 3 and 6 h. Cell lysates were
subjected to IB as indicated.
Immunofluorescence. Cells were seeded on round slide-cover slips in 12-
well plates. After 24 h, cells were transfected with the expression plasmids.
At 24 h post-transfection, cells were fixed in 3.7% PBS-buffered formaldehyde,
permeabilized with 0.05% Triton X-100 at room temperature. Cells were then
incubated for 1 h in 10% goat serum (Invitrogen, Carlsbad, CA, USA), with primary
antibody for 1 h and for 1 h with secondary antibody. Anti-mouse Texas red-
conjugated antibody-647 (Molecular Probes, Carlsbad, CA, USA) was used to
detect DNp63a. Cells were examined by confocal microscopy (Olympus, Tokyo,
Japan) under 60 magnification.
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